This inventor holds 1 USPTO granted patent. Top assignee: Novartis Ag. Active years: 2013.
Company Filing History:
Years Active: 2013
Title: Innovations in Inhalation Therapy: The Contributions of Robert J Speirs
Introduction
Robert J Speirs is an accomplished inventor based in Lynnwood, WA (US). He has made significant contributions to the field of inhalation therapy, particularly in the administration of aminoglycoside antibiotics. His innovative approaches have the potential to improve treatment outcomes for patients suffering from respiratory infections.
Latest Patents
Robert J Speirs holds a patent for "Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics." This patent describes a method for treating patients with endobronchial infections by administering a nebulized aerosol formulation. The formulation consists of a dose of less than about 4.0 ml, containing from about 60 to about 200 mg/ml of an aminoglycoside antibiotic, such as tobramycin, in a physiologically acceptable carrier. The treatment is designed to be completed in a time period of less than about 10 minutes. Additionally, the patent includes unit dose devices for the storage and delivery of these formulations.
Career Highlights
Robert J Speirs is associated with Novartis AG, a leading global healthcare company. His work at Novartis has allowed him to focus on developing innovative solutions for respiratory therapies. His dedication to improving patient care through scientific advancements is evident in his patent and ongoing research.
Collaborations
Throughout his career, Robert has collaborated with notable professionals in the field, including Peter Bruce Challoner and Barbara Ann Schaeffler. These collaborations have contributed to the development of effective treatment methods and have enhanced the impact of his work.
Conclusion
Robert J Speirs exemplifies the spirit of innovation in the medical field, particularly in inhalation therapy. His patent for aminoglycoside antibiotic formulations showcases his commitment to improving patient outcomes. His contributions continue to influence the landscape of respiratory treatment.